Phyllis Jones has a diverse and extensive litigation practice, and is a highly accomplished trial attorney. She frequently serves as lead counsel in high-profile complex mass torts involving thousands of claims, often with significant liability risks. She represents clients in both state and federal courts, as well as before arbitral panels and regulatory bodies.
Phyllis is a fellow of the American College of Trial Lawyers, and commentators from Chambers describe her as “a phenomenal trial attorney who is very agile and also terrific on her feet,” noting that “she’s incredibly convincing in front of a jury.” The American Lawyer has recognized her as a “Litigator of the Week” multiple times for her outstanding achievements.
She serves as co-chair of the firm’s market-leading Product Liability and Mass Torts practice, which is consistently recognized as one of the best in the nation. The group has been ranked Band 1: The Elite by Chambers, has received The American Lawyer’s Litigation Department of the Year award three times (2024, 2019, and 2016), and is frequently acknowledged by the National Law Journal, Law360, Benchmark Litigation, and others. Additionally, Phyllis is a member of the firm’s eight-person Management Committee.
Among her notable accomplishments, Phyllis led the trial team that won a defense verdict for Reckitt Benckiser, the parent company of Mead Johnson & Company, in mass litigation over claims that their baby formula causes a serious medical condition in preterm infants. She is currently co-lead national counsel for Meta in over a thousand mass tort cases filed by school districts and parents of teenagers, alleging that social media contributes to addiction among young users. Furthermore, she serves as lead counsel for Hain Celestial Group in multiple lawsuits alleging neurological impacts, including Autism Spectrum Disorder, from trace levels of naturally occurring metals in baby food, achieving a directed verdict in the first trial in Galveston, Texas.
Other successes include defending McKesson Corporation in the national opioid litigation, representing Boehringer Ingelheim in consecutive bellwether trials related to Pradaxa, and securing back-to-back defense verdicts in three jury trials concerning claims involving Cymbalta.
Back
